Technology ID

Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20

Lead Inventor
Kochenderfer, James (NCI)
Yang, Shicheng (NCI)
Therapeutic Areas
Development Stages
Lead IC

CD19 and CD20 are promising targets for the treatment of B-Cell malignancies.  Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression of one protein is retained when the other is lost. This suggests that a therapeutic with the ability to simultaneously target both CD19 and CD20 could represent a solution to the drawbacks of current therapies. 

Researchers at the National Cancer Institute (NCI) have developed the current invention which is an expression construct for a CAR that targets both CD19 and CD20. Specifically, a bicistronic construct has been created for expressing the two CARs from a single vector, thereby allowing for a more efficient transfection of T cells. The result is a more efficient and simultaneous targeting of both CD19 and CD20 by the same T cell.  

Competitive Advantages:

  • First in class CAR treatment targeting both CD19 and CD20 simultaneously
  • Simultaneous targeting of two antigens decreases the chance that a patient will acquire a non-responsive disease condition 
  • A single, bicistronic expression vector (rather than two separate vectors) allows for more efficient transfection of cells that can target two antigens

Commercial Applications:

  • Treatment of cancers and B cell malignancies expressing CD19, CD20, or both
Licensing Contact: